As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Bu e-kitabı satın alın ve 1 tane daha ÜCRETSİZ kazanın!
Biçim PDF ● Sayfalar 444 ● ISBN 9781466579705 ● Yayımcı CRC Press ● Yayınlanan 2013 ● İndirilebilir 6 kez ● Döviz EUR ● Kimlik 2715426 ● Kopya koruma Adobe DRM
DRM özellikli bir e-kitap okuyucu gerektirir